EMA Starts Seeking Patient Feedback Earlier For Orphan Drug MAAs
Executive Summary
A 17-month pilot by the European Medicines Agency has highlighted the benefits of obtaining the views of patients much earlier on in the review of marketing authorization applications for orphan drugs.